The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHaydale Regulatory News (HAYD)

Share Price Information for Haydale (HAYD)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.46
Bid: 0.45
Ask: 0.47
Change: -0.019 (-4.13%)
Spread: 0.02 (4.444%)
Open: 0.46
High: 0.441
Low: 0.441
Prev. Close: 0.46
HAYD Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Audited Preliminary Annual Results

30 Sep 2014 07:00

HAYDALE GRAPHENE INDUSTRIES PLC - Audited Preliminary Annual Results

HAYDALE GRAPHENE INDUSTRIES PLC - Audited Preliminary Annual Results

PR Newswire

London, September 29

Haydale Graphene Industries plc ("Haydale", the "Group" or the "Company") Audited Preliminary Results For The Year Ended 30 June 2014 Haydale Graphene Industries plc (AIM:HAYD), the Company focused on enablingtechnology for the commercialisation of graphene, is pleased to announce itspreliminary audited results for the year ended 30 June 2014. Operational Highlights (pre and post year-end): * Haydale's functionalised materials independently proven to double epoxy composite stiffness and strength - opening up the global composite market; * Ink and coatings collaboration partner secured offering fast prototyping and accelerated product development in barrier coatings, transparent conductive films and 3D printing; * Global sales reach achieved with marketing and distribution agreements; * Scale up of plasma functionalisation process on track with successful commissioning of second generation reactor with 2 similar reactors and one larger unit on order; and * Positive third party verification of plasma functionalisation process through The National Physical Laboratory. Financial Highlights: * Raised £6.6 million of new equity funds on admission to AIM in April 2014 which, together with £1.8 million of pre-IPO funds, delivered £8.4 million to the Group; * £425,000 of grant funded projects secured since IPO; * Loss after tax for the year £2.1 million (2013: £1.0 million); * Loss per share £0.28 (2013: £0.18); and * Net Cash £5.7 million (2013: £0.05 million) at year end. Ray Gibbs, CEO at Haydale, commented: "The last year has been extremely busy both internally on operationalcapability and in our global marketing effort. Critically we have sourced andpositively evaluated a number of graphene suppliers as having access to theright material is crucial to being able to offer the ultimate customer focussedsolution. With the funding now in place we look forward with optimism as we are alreadyseeing benefits from the sales, marketing and distribution agreements recentlysigned. We are experiencing strong interest, in particular from the compositemarket, arising from the exceptional results reported in June 2014 by the USbased independent research organisation Aerospace Corporation. We see thissector as being one of the earliest adopters of graphene enhanced products. Ourtechnical credibility and unique functionalisation process has been furtherendorsed by the UK National Physical Laboratory. The steps we've taken to overcome the industry challenge of taking graphenefrom the laboratory into commercial reality, are set out in my strategicreport. We believe that the significant progress made over the last year:technically, financially and commercially has created the building blocks toenable us to deliver on our planned growth." - ends - For further information please contact: Haydale Graphene Industries plc 01269 842 946 John Knowles, Chairman Ray Gibbs, Chief Executive Officer Cairn Financial Advisers LLP (Nomad) 020 7148 7900 Tony Rawlinson Paul Trendell Cantor Fitzgerald Europe (Broker) 020 7894 7000 David Foreman Paul Jewell Hermes Financial PR Trevor Phillips 07889 153 628 Chris Steele 07979 604 687 About Haydale Haydale has developed a patent-pending proprietary scalable plasma process tofunctionalise graphene and other nanomaterials. This enabling technology canprovide Haydale with a rapid and highly cost-efficient method of supplyingtailored solutions to enhance applications for both raw material suppliers andproduct manufacturers. Functionalisation is carried out through a low-pressure plasma process thattreats both mined, organic fine powder and other synthetically producednanomaterial powders, producing high-quality few layered graphenes and graphenenanoplatelets. The process can functionalise with a range of chemical groups,with the level of functionalisation tailored to the customer's needs. Gooddispersion improves the properties and performance of the host material andensures the final product performs as specified. The Haydale plasma process does not use wet chemistry, nor does it damage thematerial being processed; rather, it can clean up any impurities inherent inthe raw material. The technology is a low energy user and most importantlyenvironmentally friendly. The Haydale method is an enabling technology,allowing the Company to work with a raw material producer who seeks to addvalue to the base product and tailor the outputs to meet the targetapplications of the end user. Haydale, based in South Wales and housed in a purpose-built facility forprocessing and handling nanomaterials, is facilitating the application ofgraphenes and other nanomaterials in fields such as inks, sensors, energystorage, photovoltaics, composites, paints and coatings. www.haydale.com CHAIRMAN'S STATEMENT John Knowles, Chairman I am very pleased to present the Company's first results as a public companyfollowing our IPO on the AIM market of the London Stock Exchange on 14 April2014 ("Admission"). I am further pleased to report that we are successfullyimplementing our strategy of using partnerships and collaborations with worldrenowned companies to obtain early sales of our graphene products. This willallow us to establish a leading position in the emerging graphene market andwill also lead to licensing opportunities for our plasma technology. As part ofour strategy we will also consider suitable acquisitions where these provideaccess to sales in our target markets. Inevitably there is a lack of understanding at this stage of development overthe performance of and use of graphene. Our aim is to use our unique technologyto create understanding and acceptance of graphene by commercialising it andother related nanomaterials as quickly and effectively as possible. Industry islooking for a means to capitalise on the outstanding properties of graphene andour patent applied for graphene functionalisation technology using plasmareactors provides the material which delivers the advantages required forcommercialisation. Graphene in its pure form is not necessarily immediatelyuseful and needs various forms of chemical functionalisation to be effective.This is the Haydale speciality. As is normal with a new technology, there are many challenges we have alreadyfaced and overcome during the year under review, and we have made substantialoperational progress with our new technical team, production capability, and anew improved plasma reactor which will significantly improve our salespotential. This progress is further outlined in the Strategic Report. This year has been focussed on putting the essential elements in place for thefuture growth we expect from a fast moving and exciting sector. This growthdoes of course require substantial further work and I am pleased to say we havealready announced positive developments since our Admission, in particular thesignificant results achieved by Aerospace Corporation in doubling the strengthof epoxy composites using our functionalised graphene nanoplatelets. In theperiod, we have also generated significant new leads from major companies,which will allow us to broaden our commercial pipeline and customer base, inorder to deliver significant financial growth over the coming years. Fundraising The financial year ended 30 June 2014 was a busy and exciting one for theGroup, culminating in our AIM IPO in April 2014 which raised gross proceeds of£6.6 million. In addition, the Group raised £1.9 million pre-IPO also in thefinancial year under review. This delivered total funds of approximately £7.9million to the Group. The Group is utilising these proceeds to, inter alia, expand the Group'soperational, sales and marketing capabilities, increase the graphenefunctionalisation capacity, develop intellectual property and know-how withexternal partners and they will be sufficient to enable us to deliver ourstrategic objective of commercialising graphene. Financial results Income for the year ended 30 June 2014 amounted to £129,000 (2013: £146,000)and the retained loss was £2.1 million (2013: £1.0 million). Our cash outflowfrom operating activities was £2.1 million (2013: £0.8 million) and we endedthe year with net cash of £5.7 million (2013: £0.05 million). The cash outflowcomprised the loss before taxation of £2.2 million (2013: £1.1 million),adjusted for non-cash items and working capital changes. Operational highlights During the year under review, the operational highlights for the Group can besummarised as follows: * On 6 November 2013 Haydale signed a distribution and collaboration agreement with AMG Mining AG for the Haydale HDPlas® functionalised nanomaterials; * On 2 December 2013 Haydale listed its HDPlas® range of materials for trade on INSCX™ exchange. INSCX™ is the world marketplace for organisations seeking nanomaterials; * Haydale were awarded grant funded research work worth up to £165,000 over 3 years on bio-medical sensors: * In January 2014 Haydale were awarded ISO 9001:2008 Quality Management Systems Certification accreditation together with a recently announced award of ISO 14001: 2004 Environmental Management Systems Certification; * The National Physical Laboratory produced a favourable report in February 2014 in respect of Haydale's unique patent applied for plasma functionalisation process; and * In June 2014 Haydale announced a significant breakthrough in results from US based research institute, Aerospace Corporation endorsing the use of Haydale's GNPs in achieving more than a 100% increase in structural strength and stiffness for epoxy composites. In addition, the Group has welcomed five new directors to the Boardstrengthening its non-executive function and corporate governance capabilities.The Group has recruited key senior management to enhance our technicalcapabilities, the sales and marketing function and in operational management. Outlook The year's results are consistent with our predictions and with marketexpectations albeit that at this stage of the development of the Company,income was at a low level. We expect a significant increase in income for thecurrent financial year and our market is global. To this extent, we have madeseveral announcements regarding initiatives since the year end seeking toaddress key markets including the USA and Far East. These initiatives, togetherwith other development opportunities under consideration, lead the Board tobelieve that the Group is in a strong position to grow its operations, both athome and overseas, and to deliver its business plan for the benefit of allshareholders. In support of these strategic aims we have, since the year end: * Boosted our sales efforts and have started making good progress with our marketing and distribution partners, InVentures (USA), planarTECH (Far East), and for R&D materials through INSCX™ and the specialist web based supplier, Goodfellow; * Started to capitalise on the reputation and support from our ink and coating partner, the Welsh Centre for Printing and Coating, with a development program of specialist products; * Commenced a program of capacity expansion in our production facility to accommodate increases in technical staff and analytical and processing equipment; and * Reached an advanced discussion stage with specialist plasma equipment manufacturer Tantec A/S over a long term supply arrangement and in the meantime have already placed an order with two units for delivery in December 2014 and a larger technology demonstrator in early 2015 for future licensees. I would like to thank the staff, the Board and the Group's external advisersfor their hard work over the last year. I would also like to thank RichardNewton-Jones and David Cheyne, who stepped down from the Board earlier thisyear, for their support and contributions over a number of years. This will be an important year for Haydale. With the financial strengthprovided by our IPO, coupled with the support of a strong Board providing awealth of experience across a wide skill spectrum, the Group is confident ofhaving a successful year. I look forward to reporting on the futuredevelopments of the Group. John Knowles Chairman 29 September 2014 STRATEGIC REPORT The directors present their Strategic Report for the year ended 30 June 2014. PRINCIPAL ACTIVITIES Haydale Graphene Industries Plc is the AIM listed company with a number ofsubsidiaries, the principal one being Haydale Limited ("Haydale"). Haydale wasincorporated in 2003 and sources, handles and processes nanomaterials with asuite of prototyping and analytical equipment, to facilitate the commercialapplication of, initially, graphenes for customers worldwide. Our process is,however, equally applicable to other nanomaterials. Haydale is strategically well positioned in that it can source the mostappropriate graphene and other nanomaterials feedstock from suppliers that, inconjunction with its unique proprietary plasma treatment (known asfunctionalisation), produces a tailored customer focussed solution. This is onethat enables the nanoparticles (e.g. graphene) to disperse uniformly in thetarget material. Proper dispersions are essential in enabling the potential ofgraphene and other nanomaterials to be realised. What is Graphene? Carbon is an amazing material and is the basis of all organic living materials.It is also found naturally in different forms or allotropes, including diamond,graphite and coal. In 2004, scientists Professors Andre Geim and KonstantinNovoselov at the University of Manchester first isolated and characterisedgraphene. In 2010, they received the Nobel Prize in Physics for their groundbreaking research which elevated this material to the world stage, sendingripples of excitement through the academic, investment and corporate world. The term `graphene' which originally described a single 2-D sheet of carbonatoms, has gradually been widened to encompass both sheet and flake carbonmaterials produced by a variety of methods. Engineering applications tend tofocus on the use of graphene nanoplatelets (GNPs). These materials can beproduced by a `top down' production method, involving the exfoliation of minedgraphite to produce flakes, or by a `bottom up' production method, such aschemical vapour deposition from a carbon source. Experimental characterisationhas revealed that graphene is mechanically 200 times stronger than steel, hasin-plane electrical and thermal conductivity higher than copper, and has anincredible surface area of over 2,500m2 per gram. The particulate graphene formcan be produced in large quantities in various thicknesses. Few layer graphene(FLG) comprises several atomic layers of carbon, and so-called many-layergraphene, or graphene nanoplatelets (GNPs) typically comprise 5-100 layers.Thereafter the material can be described as graphite. The challenge is how to translate these properties measured in the laboratoryinto commercial applications, especially as graphene is effectively inert? Thisis where Haydale comes in. Commercialisation of Graphene Realising the full benefits of nanomaterials and especially graphene is rarelyeasy. They need to be optimised for incorporation into the intermediatematerial or end use application. When you get it right, the results can bespectacular. In June 2014, Haydale announced the outstanding results achievedby the USA based Aerospace Corporation in incorporating our suitablyfunctionalised GNPs in reinforcing epoxy resins and composites. To date, many tens of millions of dollars has been invested by governments andcorporations seeking ways and means to capitalise on the significant benefitsoffered by graphene. Haydale is not a manufacturer of the raw graphene, ratherwe are a solutions provider focussed on the early adoption andcommercialisation of graphene. We have an enabling technology utilising aunique functionalisation process on nanomaterials, specifically graphene, as ameans of delivering improved product performance. We have the capability now tosource and use, both organic and synthetically produced flake graphene, and tomodify the surface of the graphene with specific chemical functional groupstailored to the requirements of the end user's application. This process isknown as functionalisation. Applying the correct functionalisation has twoimmediate benefits, namely, the promotion of: * homogeneous dispersion in a solution (ie avoiding agglomeration); and * chemical interaction or bonding with a substrate or matrix. Functionalisation is carried out through a low pressure plasma process thattreats both organic mined fine powder and other synthetically producednanomaterial powders producing high quality few layered graphenes and graphenenanoplatelets. The process can functionalise with a wide range of chemicalgroups, where the concentration of chemicals can be tailored to the customerneeds. Good dispersion improves the properties and performance of the hostmaterial and ensures it delivers to the desired specification. There continues to be significant government and institutional funding aimed atapplications for graphene. We are working with and are in discussions withseveral large multi-national corporations and universities to create"intermediate products" such as conductive inks, epoxy composites and coatings. The general use of nanoparticles is well accepted in the pharmaceutical,cosmetic and chemical industries. Adopting a new material such as graphenehowever takes time, requiring sampling, testing and evaluation. Often this isdone in conjunction with collaboration partners, primarily end users who arewilling to consider new innovative materials in seeking a competitiveadvantage. Our approach has been to work with the material suppliers and/or theend user to develop intermediate products that the manufacturer can use toimprove a product offering. Our market focus is targeted on sectors where weconsider early adoption of new innovative materials is commonplace. Often, takeup of a new material is hampered by the need to invest significant sums in newplant and equipment and discard the existing machinery. We consider that themarkets that we have focussed on, namely, energy harvesting, inks/coatings andspecifically composites have less inbuilt inertia to change and are earlyadopters of such new materials. OPERATING REVIEW In the year under review, and in the three months post year-end, the Companyhas made significant progress in building its human resources, production andsales capability. The objective has been to underpin the strategic markets weare focussed on to deliver the growth required to move to an operating profitand, as highlighted above, within the past year, Haydale has signed a series ofdistribution and partnership agreements to help achieve this goal. R&D Materials Access to the right nanomaterials is crucial to being able to offer theultimate customer focussed solution. In November 2013, we agreed an exclusivedistribution arrangement and a supply contract with AMG Mining AG. Since thenwe have seen, evaluated and qualified many different suppliers to provide uswith a broad range of materials to choose from which will best suit the endusers' application. All have to be able to demonstrate continuity of supply andconsistency of product which are critical components in the supply chain. In addition we have distribution outlets now for some of our functionalisedgraphene based materials through Graphene Supermarket, INSCX™ and most recentlywith leading global materials supplier, Goodfellow. These collaborations areprincipally to focus on distributing Haydale's line of functionalised graphenenanoplatelets (GNPs) which are sold under the trade name, HDPlas®. Inks and Coatings Having tested the market for some time with a conductive "Graphene" based ink,the agreement with the Welsh Centre for Printing and Coating (WCPC), signed inJuly 2014, has enabled us to now launch a commercially available conductiveink. WCPC are investigating the exploitation of functionalised graphene, andother carbon nano-materials developed by Haydale, in areas such as transparentconductive films, barrier coatings and 3D printing. Composites We announced in June 2014 the results of independent research by the AerospaceCorporation in the USA, which demonstrated substantial improvements in epoxycomposite strength and stiffness. For the composites market, Haydale's plasmaprocess has the potential to offer the tailored functionalisation of graphenenanomaterials whilst maintaining structural integrity thus eliminating a keybarrier to the commercialisation of graphene in this sector. We are focussed on developing our composite offerings and seeking industrialpartners who can design, develop and commercialise advanced polymer compositematerials on a global basis. In a number of instances we have commencedcommercial discussions. With the right partners, we believe that the Haydalenanomaterials will show demonstrable clear technical, economic andenvironmental benefits over existing structures currently manufactured intraditional materials such as steel, aluminium, wood or concrete. Energy Harvesting We are working on several potential strategic alliances in this complex market.Our team of energy experts have identified a number of specialist sectors forexploitation, where our novel materials and functionalisation can make adifference. We would expect to make good progress in this sector over thecoming year which is likely to include the work done by target partners in theenergy market including key University knowledge and testing facilities. Sales strategy We continue to invest in personnel to capitalise on the increasing momentumachieved over the last year. Aiming to vigorously pursue our commercialisationstrategy, we have recruited a Haydale business development director and 2support managers with polymer coatings and ink expertise to exploit our growingtechnical reputation. As part of our global sales strategy, we engaged with twoorganisations in July 2014 who can explore and bring significant sales andcollaboration opportunities in the Far East (planarTECH) and USA (InVentures).We believe that the use of agents who are already well established andrecognised in their specific areas of expertise will significantly reduce thetime required for Haydale to become well known in these territories. We are nowable to cost effectively engage customers across the globe to developapplication specific, graphene enhanced materials. There are encouraging signsof early interest from both markets in our materials, process and products. Grant funding Sampling of the functionalised materials continues as a means to engage withindustrial corporations and manufacturers and to enter collaborations andconsortia on dedicated projects. Since April 2014, we have secured focussed andimportant grant funded work from which our future income will be over £425,000.This includes one current and one future project partly funded by Innovate UK(previously known as the Technology Strategy Board). In October 2014, we alsostart on a European project in conjunction with the German based FraunhoferGroup (and others) to develop a high resolution roll to roll printing ofbio-compatible graphene/protein multilayers for bio medical applications. Thisproject is expected to be worth over £175,000 in income to the Group over thenext 3 years. In addition, although relatively small, we have been included in a successfulUK defence contract feasibility study to develop a prototype coating for anovel hydrophone under water system. A positive outcome in this project, whichis scheduled for completion in the current financial year, could lead tosignificant additional work. The defence sector is an area that we consider hassignificant potential for the range of products we are starting to develop. Operations and technical In the year under review, headcount more than doubled to 10 and post year-endwe have added a further 2 technical staff with a further 3 budgeted joiners forthe remainder of the current financial year. The appointment of Dr ChrisSpacie, as Group Chief Technical Officer from Morgan Advanced Materials inSeptember 2013, has been crucial in ensuring the production and processingcapability was controlled and reproducible. Our functionalisation process waspositively commented on by the National Physical Laboratory in February 2014. We now have an established processing and treatment facility capable ofsupplying tonnes of graphene per year exactly to the customers' specification.Haydale has developed a patent pending proprietary scalable plasma process tofunctionalise graphene and other nanomaterials. Switching plasma reactorsuppliers to Tantec A/S has enabled the business to increase capacity andimprove the functionalisation process incorporating state of the art latesttechnology. We are in advanced discussion with Tantec A/S over a long termsupply agreement and have already ordered two new reactors with deliveryexpected in late 2014. These units are expected to remain in the UK asadditional capacity for our immediate future although certain customers havecommenced enquiries on licensing a reactor. Consequently we have also ordered areactor capable of annually functionalising multiple tonnes of material. Thiswill act as further capacity but also promoted as the technology demonstratorwhich is seen as the reactor that larger-scale licensees will require. As part of our expansion plans we have commenced work on creating additionaldedicated laboratory space in a smaller unit of 2,500 sq ft adjacent to our5,000 sq ft main factory in Ammanford. This facility will enable us to rapidlydevelop and test the intermediate products for the defined market sectors aboveas a means of assisting the sales team with their marketing and promotionefforts. Furthermore, as part of our commercialisation strategy, we have openeda small sales and marketing office within Reading University. Licensing Licensing is a key part of our sales strategy and we are pleased with theinitial discussions held with a number of blue-chip organisations to date onthe possibility of licensing our technology and our reactors to the customersown locations. Whilst there can be no guarantee at this stage that agreementswill be completed, we anticipate that the terms of licensing agreements will bein line with the Board's expectations. FINANCIAL REVIEW The Financial Review should be read in conjunction with the consolidatedfinancial information of the Group and the notes thereto. The consolidatedfinancial statements are presented under International Financial ReportingStandards as adopted by the European Union. Statement of Comprehensive Income In the year under review, the Group primarily focussed on continuing to improveits proprietary plasma functionalisation process, with a view to commencing asales and marketing push following the Group's admission to AIM. Accordingly,income for the year was £129,000 (2013: £146,000) with a loss from operationsof £2.2 million (2013: £1.1 million). Support from grant funded projectstotalled £110,000 in the period under review (2013: £55,000). R&D expenditure for the year amounted to £0.4 million (2013: £0.5 million),with salaries for technicians, lab assistants and scientific personnel, as in2013, accounting for the majority of the spend. Other administrative costs forthe year totalled £1.9 million (2013: £0.7 million), a significant proportionof which were incurred as professional fees in connection with the Company'sadmission to trading on AIM. The loss after tax for the year was £2.1 million (2013: £1.0 million) and theloss per share was £0.28 (2013: £0.18). Statement of Financial Position and Cashflows As at 30 June 2014, net assets amounted to £6.8 million (2013: £1.0 million),including net cash balances of £5.7 million (2013: £0.05 million). At the yearend and as at today, the Group does not have any bank or other debt (save fortrade payables in the ordinary course). Net cash outflow from operatingactivities for the year was £2.1 million (2013: £0.8 million), the maincontributing factor being the operating loss of £2.2 million. The Group was principally funded during the period by new equity share issuesproceeds (net of costs) amounting to £7.8 million (2013: £0.8 million),together with grant funding income of £0.1 million (2013: £0.06 million). Capital Structure and Funding As at 30 June 2014, the Company had 11,247,823 Ordinary Shares in issue, whichnumber is unchanged at the date of this report. On 20 March 2014, the Companyconducted a bonus issue of shares on the basis of 80 new Ordinary Shares foreach existing ordinary share by capitalising £158,320 of the Company's sharepremium account. In addition, the remaining balance standing to the credit ofthe Company's share premium account was reduced by £4,742,000 with the amountso reduced being credited to a reserve. CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME For the year ended 30 June 2014 Note Year Year ended ended 30 June 30 June 2014 2013 £'000 £'000 REVENUE 19 91 Other income 110 55 129 146 Administrative expenses Costs of admission to AIM (424) - Research and development expenditure (416) (478) Share based payment expense (67) (4) Other administrative expenses (1,424) (720) (2,331) (1,202) LOSS FROM OPERATIONS (2,202) (1,056) Finance costs (14) (5) LOSS BEFORE TAXATION 4 (2,216) (1,061) Taxation 71 69 LOSS FOR THE YEAR / TOTAL COMPREHENSIVE LOSS (2,145) (992)ATTRIBUTABLE TO OWNERS OF THE PARENT Loss per share attributable to owners of theParent Basic (£) 5 (0.28) (0.18) Diluted (£) 5 (0.28) (0.18) CONSOLIDATED STATEMENT OF CHANGES IN EQUITY For the year ended 30 June 2014 Share Share Share-based Retained Total capital premium payment profits reserve £'000 £'000 £'000 £'000 £'000 At 1 July 2012 1 2,420 - (1,235) 1,186 Total comprehensive loss for - - - (992) (992)the year Recognition of share-based - - 4 - 4payments Issue of ordinary share - 826 - - 826capital Transaction costs in respect - (32) - - (32)of share issues At 30 June 2013 1 3,214 4 (2,227) 992 Total comprehensive loss for - - - (2,145) (2,145)the year Recognition of share-based - - 67 - 67payments Issue of ordinary share 66 8,443 - - 8,509capital Transaction costs in respect - (623) - - (623)of share issues Bonus issue of £0.02 158 (158) - - -ordinary shares Reduction in share premium - (4,742) - 4,742 - At 30 June 2014 225 6,134 71 370 6,800 CONSOLIDATED STATEMENT OF FINANCIAL POSITION As at 30 June 2014 30 June 30 June 1 July 2014 2013 2012 £'000 £'000 £'000 ASSETS Non-current assets Goodwill 51 51 51 Intangible assets 554 590 625 Property, plant and equipment 527 519 426 1,132 1,160 1,102 Current assets Inventories 22 24 25 Trade receivables 8 2 36 Other receivables 244 85 74 Corporation tax 63 64 49 Cash and bank balances 5,677 54 149 6,014 229 333 TOTAL ASSETS 7,146 1,389 1,435 LIABILITIES Current liabilities Trade and other payables 300 290 244 Deferred income 46 107 5 TOTAL LIABILITIES 346 397 249 TOTAL NET ASSETS 6,800 992 1,186 EQUITY Capital and reserves attributable toequity holders of the parent Share capital 225 1 1 Share premium account 6,134 3,214 2,420 Share-based payment reserve 71 4 - Retained profits 370 (2,227) (1,235) TOTAL EQUITY 6,800 992 1,186 CONSOLIDATED STATEMENT OF CASH FLOWS For the year ended 30 June 2014 Year Year ended ended 30 June 30 June 2014 2013 £'000 £'000 Cash flow from operating activities Loss before taxation (2,216) (1,061) Adjustments for:- Amortisation of intangible assets 36 35 Depreciation of property, plant and equipment 137 120 Share-based payment charge 67 4 Finance costs 14 5 Operating cash flow before working capital (1,962) (897)changes (Increase) / decrease in inventories (2) - (Increase) / decrease in trade and other (165) 23receivables (Decrease) / increase in payables and (51) 34deferred income Cash used in operations (218) 57 Income tax received 72 53 Net cash flow from operating activities (2,108) (787) Cash flow used in investing activities Purchase of property, plant and equipment (147) (226) Proceeds from disposal of property, plant and 2 12equipment Finance costs (5) (4) Net cash flow in investing activities (150) (218) Cash flow used in financing activities Proceeds from issue of share capital 8,425 826 Share issue costs (623) (31) Grants received - 115 Issue of convertible debt 79 - Net cash flow from financing activities 7,881 910 Net increase / (decrease) in cash and cash 5,623 (95)equivalents Cash and cash equivalents at beginning of the 54 149financial year Cash and cash equivalents at end of the 5,677 54financial year 1. General information Haydale Graphene Industries Plc (the "Company") and its subsidiaries (togetherthe "Group") are focussed on enabling technology for the commercialisation ofgraphene. The Company is a public limited company which is listed on AIM on the LondonStock Exchange and is incorporated and registered in England and Wales. TheCompany's registered office is Clos Fferws, Parc Hendre, Capel Hendre,Ammanford, Carmarthenshire, SA18 3BL. 2. Group Annual Report and Statutory Accounts The financial information of the Group set out above does not constitute"statutory accounts" for the purposes of Section 435 of the Companies Act 2006.The financial information for the year ended 30 June 2014 has been extractedfrom the Group's audited financial statements which were approved by the Boardof directors on 29 September 2014 and will be delivered to the Registrar ofCompanies for England and Wales in due course. The report of the auditor onthese financial statements is unqualified, did not include any references toany matters to which the auditors drew attention by way of emphasis withoutqualifying their report and did not contain a statement under Section 498(2) orSection 498(3) of the Companies Act 2006. 3. Basis of preparation Whilst the financial information included in this preliminary announcement hasbeen prepared in accordance with the recognition and measurement criteria ofInternational Financial Reporting Standards ('IFRSs') as adopted by theEuropean Union, this announcement does not itself contain sufficientinformation to comply with those IFRSs. This financial information has beenprepared in accordance with the accounting policies set out in the June 2014report and financial statements. 4. Loss before taxation Loss before taxation is arrived at after charging: 2014 2013 £'000 £'000 Research and development: - current period's expenditure 380 443 - amortisation of capitalised 36 35expenditure Depreciation of property, plant and 137 120equipment Operating lease rentals: - land and buildings 34 28 - plant and machinery 1 - 5. Loss per share The calculations of loss per share are based on the following losses and numberof shares: 2014 2013 £'000 £'000 Loss after tax attributable to (2,145) (992)owners of the Haydale GrapheneIndustries Group Weighted average number of shares: * Basic and Diluted 7,755,175 5,661,495 Loss per share: * Basic (£) and Diluted (£) (0.28) (0.18) The loss attributable to ordinary shareholders and weighted average number ofordinary shares for the purpose of calculating the diluted earnings perordinary share are identical to those used for basic earnings per share. Thisis because the exercise of share options would have the effect of reducing theloss per ordinary share and is therefore not dilutive under the terms of IAS33. 6. Further information A copy of this preliminary statement will be available to download on theGroup's website www.haydale.com. Copies of the Annual Report and Accounts,together with the notice convening the annual general meeting, will be postedto shareholders in due course at which time the Annual Report and Accounts willbe made available to download on the Group's website, www.haydale.com, inaccordance with AIM Rule 26.
Date   Source Headline
2nd May 20247:00 amRNSGrant of Share Options and PDMR Dealing
12th Mar 20247:00 amRNSInterim Results
26th Jan 20247:00 amRNSGrant of Options & Surrender of Existing Options
22nd Jan 20247:00 amRNSHaydale selected for Innovate UK Scaleup Programme
7th Dec 202311:36 amRNSResult of AGM
7th Dec 202311:34 amRNSDirectorate Change
6th Dec 20237:00 amRNSHaydale awarded SMART funding
16th Nov 20232:31 pmRNSHolding(s) in Company
13th Nov 20237:00 amRNSPosting of Annual Report & Notice of AGM
1st Nov 20237:00 amRNSTotal Voting Rights
26th Oct 20237:00 amRNSFinal Results
9th Oct 20238:23 amRNSHolding(s) in Company
5th Oct 20231:43 pmRNSDirector/PDMR Shareholding & Total Voting Rights
4th Oct 20234:46 pmRNSHolding(s) in Company
3rd Oct 20233:48 pmRNSResult of General Meeting
2nd Oct 20237:00 amRNSTotal Voting Rights
22nd Sep 20234:30 pmRNSResult of Retail Offer and Total Voting Rights
15th Sep 20236:12 pmRNSResult of Fundraising
15th Sep 20234:00 pmRNSLaunch of Retail Offer
15th Sep 20233:00 pmRNSProposed Placing, Subscription & Retail Offer
15th Sep 20237:00 amRNSWarrant Expiry, Block Admission Cancellation & TVR
22nd Aug 20237:00 amRNSCollaboration with PETRONAS
4th Aug 20231:02 pmRNSHolding(s) in Company
2nd Aug 20237:00 amRNSDirectorate Change
24th Jul 20237:00 amRNSContract Award
13th Jul 20237:00 amRNSHaydale Delivers LPHW Prototype for Cadent
21st Jun 20237:00 amRNSTrading Update
5th Jun 20237:00 amRNSDirectorate Change
24th May 20237:00 amRNSHaydale to Contribute to the Development of FCHEVs
3rd May 20237:00 amRNSSMART Innovation to Accelerate Graphene Products
26th Apr 20233:06 pmRNSGrant of Share Options
12th Apr 20237:00 amRNSHaydale and Saint-Gobain Collaborate on hBN
16th Mar 20237:00 amRNSHaydale and City Energy Develop UFH with Plumbase
14th Mar 20238:15 amRNSBlock listing Interim Review
10th Mar 202311:05 amRNSSecond Price Monitoring Extn
10th Mar 202311:00 amRNSPrice Monitoring Extension
10th Mar 20237:00 amRNSDirectorate Change
1st Mar 20237:00 amRNSInterim Results
28th Feb 202311:38 amRNSHaydale and GEIC Proud to Partner for a Sixth Year
21st Feb 20237:00 amRNSRega Turns to Graphene to Improve Sound Quality
14th Feb 20237:00 amRNSInnovate UK Grant to Image 2D Materials Awarded
7th Feb 20237:00 amRNSHaydale Paddles Forward with Norse Kayaks
30th Jan 20237:00 amRNSNotice of Interim Results
26th Jan 20237:00 amRNSCeramycGuard™ on Trial with United Utilities
20th Dec 20227:00 amRNSGraphene-Enhanced Prepreg Extends Tool Life
1st Dec 20227:00 amRNSFinalist for Collaborate to Innovate Awards
30th Nov 20229:22 amRNSGrant of Warrants
29th Nov 20221:55 pmRNSResult of AGM
15th Nov 20227:00 amRNSGrant of share options and PDMR dealings
1st Nov 20227:00 amRNSDirectorate Change and Posting of Annual Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.